Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

PURPOSE: Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studied a real-world cohort to identify risk factors for cardiotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwer, N. I., Steenbruggen, T. G., van Rosmalen, J., Rier, H. N., Kitzen, J. J. E. M., van Bekkum, M. L., Tije, A. J. Ten, de Jong, P. C., Drooger, J. C., Holterhues, C., Smorenburg, C. H., Kofflard, M. J. M., Boersma, E., Sonke, G. S., Levin, M.-D., Jager, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019427/
https://www.ncbi.nlm.nih.gov/pubmed/33394273
http://dx.doi.org/10.1007/s10549-020-06039-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019427/
https://www.ncbi.nlm.nih.gov/pubmed/33394273
http://dx.doi.org/10.1007/s10549-020-06039-w

Ejemplares similares